Multiple Advantages of GLP-1 Agonists in Type 2 Diabetes With Cirrhosis of the Liver

 Multiple Advantages of GLP-1 Agonists in Type 2 Diabetes With Cirrhosis of the Liver

NEW OBSERVATIONAL DATA: In people with type 2 diabetes (T2D) and compensated liver cirrhosis, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use reduces the risk for death, cardiovascular disease, decompensated cirrhosis, and liver failure.

                            METHODOLOGY: Data from Taiwan's National Health Insurance Research Database were used in this population-based cohort study.

467 matched pairs of GLP-1 RA users and nonusers with T2D and compensated liver cirrhosis (mean age, 57) were created using propensity-score matching.

In multivariable-adjusted Cox proportional hazards models, all-cause mortality, cardiovascular events, decompensated cirrhosis, and other important outcomes were compared.

TAKEAWAY: Death rates per 1000 person-years during a mean follow-up of around 3 years were 27.5 in GLP-1 RA users compared

Comments

Popular posts from this blog

PROS AND CONS OF INTERNET BANKING

Stale water, brambles in dengue-drive center

FIVERR has become a go-to resource for many companies looking to outsource their media and marketing needs. It provides a wide range of services at affordable prices and ensures that all projects are completed on time. Furthermore, it has a vast network of experienced professionals who specialize in various aspects of media and marketing. This makes it easier for businesses to find the right person for their project without having to spend too much time doing research.